Publications

Publications

Filter Results: (1,245) Arrow Down
Filter Results: (1,245) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 24 of 1,245 Results →

    Nitin Nohria

    Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

    As Dean, building on... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • Web

    Employment Data Trends

    Employment Data Trends Employment Data Trends Trends Career Data Internship Data Trends by Industry 2020 2021 2022 2023 2024 Consulting 24% 23% 26% 25% 18% Consumer Products 3% 3% 3% 4% 3% Entertainment / Media 2% 3% 3% 1% 3% Health Care 7% 6% 5% 5% 6% Biomed / View Details
    • 21 Feb 2018
    • Research & Ideas

    When a Competitor Abandons the Market, Should You Advance or Retreat?

    Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
    Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical

      Rosabeth M. Kanter

      Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • Web

      All Industries

      Entertainment / Media 3% $150k 25th Percentile Base $165k Median $184k 75th Percentile Base $13k 40% Receiving $21k 60% Receiving Health Care 6% + – Expand Row $145k 25th Percentile Base $165k Median $185k 75th Percentile Base $30k 66% Receiving $29k 71% Receiving... View Details
      • 18 Apr 2023
      • Research & Ideas

      The Best Person to Lead Your Company Doesn't Work There—Yet

      within their own ranks. “What you really do need is knowledge of that specific industry, whether it's pharmaceutical or manufacturing or hospitality or rocket science.” The findings suggest an active market for CEOs, who are lured to... View Details
      Keywords: by Rachel Layne; Financial Services

        Debora L. Spar

        Debora Spar is the Jaime and Josefina Chua Tiampo Professor of Business Administration at Harvard Business School and Senior Associate Dean for Business and Global Society. Her current research focuses on issues of gender and technology, and the interplay between... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • January–February 2023
        • Article

        Forecasting COVID-19 and Analyzing the Effect of Government Interventions

        By: Michael Lingzhi Li, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis and Dimitris Bertsimas
        We developed DELPHI, a novel epidemiological model for predicting detected cases and deaths in the prevaccination era of the COVID-19 pandemic. The model allows for underdetection of infections and effects of government interventions. We have applied DELPHI across more... View Details
        Keywords: COVID-19 Pandemic; Epidemics; Analytics and Data Science; Health Pandemics; AI and Machine Learning; Forecasting and Prediction
        Related
        • 15 Jan 2019
        • First Look

        New Research and Ideas, January 15, 2019

        December 19, 2018 NEJM Catalyst It's Time to Reform the Orphan Drug Act By: Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=55448 January 2019... View Details
        Keywords: Dina Gerdeman

          Youngme Moon

          Youngme Moon is the Donald K. David Professor of Business at Harvard Business School. Professor Moon's research sits at the intersection of brand strategy and culture, with a particular focus on the emergent AI economy. She is the author of the bestselling book, View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
          • Web

          HBS - The year in Review

          standards, and values of the School. The recipients were honored during the Class Day ceremony. The 2023 Award recipients were Reshma Kewalramani MD, FASN (GMP 18, 2015) CEO and President, Vertex Pharmaceuticals Depelsha Thomas McGruder... View Details
          • Research Summary

          Regulatory Change/Business-Government Relations

          “Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”

          Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details

          Keywords: Business ＆ Government Relations; Regulations; Regulatory Capture; Pharmaceutical Industry; United States

            Kyle R. Myers

            Kyle Myers is an assistant professor of business administration in the Technology and Operations Management unit. He teaches the first-year Technology and Operations Management course.

            Professor Myers studies the economics of innovation. His research is at... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • Research Summary

            Clinical Trials as a setting for Health Policy and Management Research

            The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details
            • October 1982 (Revised May 1992)
            • Case

            Johnson & Johnson: The Tylenol Tragedy

            By: Stephen A. Greyser
            In October 1982, Johnson & Johnson was confronted with a major crisis when seven deaths were attributed to poisoned Tylenol. The case reviews the facts as known a week after the incident occurred, and raises a wide range of questions regarding consumer behavior,... View Details
            Keywords: Consumer Behavior; Corporate Social Responsibility and Impact; Competitive Strategy; Crisis Management; Health Care and Treatment; Pharmaceutical Industry
            Related
            • November–December 2015
            • Article

            Active Postmarketing Drug Surveillance for Multiple Adverse Events

            By: Joel Goh, Margrét V. Bjarnadóttir, Mohsen Bayati and Stefanos A. Zenios
            Postmarketing drug surveillance is the process of monitoring the adverse events of pharmaceutical or medical devices after they are approved by the appropriate regulatory authorities. Historically, such surveillance was based on voluntary reports by medical... View Details
            Keywords: Drug Surveillance; Health Care; Stochastic Models; Queueing; Diffusion Approximation; Brownian Motion; Health Care and Treatment; Analytics and Data Science; Analysis
            Related
            • Forthcoming
            • Article

            Achieving Epilepsy Care for All: Ecosystem-Based Transformation

            By: Susanna Gallani, Bernice Martin Lee and Lidia M. V. R. Moura
            Epilepsy exemplifies many of the systemic challenges of modern health care— fragmented care delivery, inequitable access, financial strain, and so on. The current “system of systems” (SoS) structure of U.S. health care fosters siloed operations among its member systems... View Details
            Keywords: Healthcare Delivery; Epilepsy; Seizures; Health Care and Treatment; Health Disorders; Equality and Inequality; Framework; Service Delivery
            Related
            • 07 Jan 2010
            • Working Paper Summaries

            International Differences in the Size and Roles of Corporate Headquarters: An Empirical Examination

            Keywords: by David Collis, David Young & Michael Goold
            • Research Summary

            Putting Patients First: Marketing Strategies for Treating HIV in Developing Nations

            It is more than mere coincidence that the highest rates of HIV occur in the world’s poorest countries. Of the over 40 million people currently living with HIV, 95 percent are in the developing world. The first half of this paper explores the economics of HIV and... View Details
            • 13 Jul 2020
            • Research & Ideas

            Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk

            As chairman and CEO of the leading vaccine producer in the world, pharmaceutical giant Merck & Co., Ken Frazier has one of the highest-profile positions in global business. But Frazier, who is leading one of the firms on a charge to... View Details
            Keywords: by Staff; Pharmaceutical